Search This Blog

Friday, May 18, 2018

Sarepta target upped by Goldman: ‘Multiple shots on DMD’

Goldman Sachs raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $127.00 (from $84.00) while maintaining a Buy rating.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)